Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal dosing of piperacillin-tazobactam in ICU patients: extended vs continuous infusion
2010-021050-20Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Jul 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of piperacillin + tazobactam in bacterial disease (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Primary pharmacokinetic comparison. Started Jul 2010; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2010-021050-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021050-20.